Sodium Oxybate

Introduction Overview

Generic Name

sodium oxybate

Brand Name

Xyrem

Dosage Form

oral solution

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics

Pharmacokinetics

Absorption:
Sodium oxybate, the active component of Xyrem, is administered orally as a solution. It is rapidly absorbed from the gastrointestinal tract, with bioavailability exceeding 80%. Peak plasma concentrations (Cmax) are usually achieved within 30 to 60 minutes post-dose. Food can affect absorption; it is recommended to wait at least two hours after eating before administration to optimize absorption. The rapid onset of action is consistent with swift uptake and central nervous system penetration, contributing to rapid sleep induction observed clinically.

Distribution:
Sodium oxybate is distributed extensively throughout body tissues, including the central nervous system (CNS), crossing the blood-brain barrier efficiently to exert its pharmacologic effects. The volume of distribution is relatively large, reflecting this tissue penetration. It does not appreciably bind to plasma proteins, which facilitates its distribution to the brain and other organs. Given its CNS depressant activity, the distribution to sensitive neuronal sites is clinically significant.

Metabolism:
Sodium oxybate undergoes extensive metabolism primarily through the GHB metabolic pathway. It is metabolized via cytosolic enzymes to succinic semialdehyde, which is further converted to succinate and enters the Krebs cycle ultimately yielding carbon dioxide and water. This metabolism engages GHB dehydrogenase and succinic semialdehyde dehydrogenase enzymes, with minimal cytochrome P450 involvement, limiting drug-drug interaction risk.

Elimination:
Elimination occurs mostly through metabolism (>95%), with less than 5% of unchanged drug excreted renally. The elimination half-life is relatively short, approximately 0.5 to 1 hour, which supports the clinical dosing strategy of two nightly doses to maintain therapeutic effect throughout the night. Renal impairment can modestly affect clearance, necessitating caution and possible dose adjustment in patients with kidney dysfunction. The rapid metabolic clearance and short half-life contribute to the drug’s sedative profile and require dosing at bedtime with a second dose during the night.

Dosage Forms

Available Dosage Forms:
Xyrem is available solely as an oral solution containing sodium oxybate at a concentration of 0.5 g/mL. It is supplied in a 180 mL bottle equipped with a child-resistant cap to enhance safety given the drug's abuse potential. The solution is intended for dilution with approximately ¼ cup of water prior to administration and comes with pharmacy-provided dosing containers designed for precise measured dosing and secure storage.

Dosages for Adults and Adolescents:
For the treatment of narcolepsy-associated cataplexy or excessive daytime sleepiness in adults, initial dosing begins at 2.25 grams administered orally at bedtime, followed by a second 2.25 gram dose taken 2.5 to 4 hours later during the night. The dose is titrated weekly in increments of 1.5 grams per night to an effective therapeutic range of 6 to 9 grams per night, divided equally over the two doses. The maximum dose is 9 grams per night split into two doses.

Dosages for Children:
Xyrem is approved for pediatric use in patients aged 7 years and older with narcolepsy. In children, dosing is weight-based and carefully titrated according to clinical response and tolerability. The initial dose and increments for titration differ from adults and require close medical supervision referencing specific pediatric prescribing information to ensure safety and efficacy.

Specific Patient Populations:
In patients with hepatic impairment, the recommended dosage is approximately half that of normal dosages administered per night, divided into two doses, to account for altered metabolism and increased drug exposure. Patients with renal impairment require careful monitoring, although no specific dosage adjustments are universally mandated; clinical judgment guides dosing modifications. Due to its high sodium content, caution is warranted in patients with cardiovascular disease, hypertension, kidney disease, or those on sodium-restricted diets, with close clinical monitoring.

Mechanism Of Action

Sodium oxybate, the active ingredient in Xyrem, acts as a central nervous system (CNS) depressant with a unique mechanism involving gamma-hydroxybutyrate (GHB) receptors and GABAB receptors. It is a structural analogue of gamma-aminobutyric acid (GABA), specifically engaging GHB-specific receptors and GABAB receptors in the brain. This dual receptor activity modulates neuronal excitability and enhances slow-wave sleep, which is critically impaired in patients with narcolepsy.

At the molecular level, sodium oxybate binds to GABAB receptors located on presynaptic and postsynaptic neurons, resulting in increased inhibitory neurotransmission through the activation of potassium channels and inhibition of calcium channels. This action hyperpolarizes neuronal membranes, decreasing excitatory neurotransmitter release and reducing neuronal firing. Concurrently, by binding to GHB receptors, which are predominantly found in the brain, particularly in the thalamus and hippocampus, sodium oxybate modulates dopaminergic and glutamatergic pathways, influencing wakefulness and sleep architecture.

Clinically, these mechanisms translate into enhanced slow-wave (delta) sleep, which is associated with restorative deep sleep. The improvement in the quality and consolidation of deep sleep reduces the excessive daytime sleepiness characteristic of narcolepsy and diminishes the frequency and severity of cataplexy episodes. Clinical studies support the relationship between enhanced slow-wave sleep and symptomatic improvement, validating the pharmacologic rationale.

Compared to other CNS depressants, sodium oxybate’s modulation of GABAB and GHB receptors offers a distinct pharmacodynamic profile. While benzodiazepines act mainly on GABAA receptors potentiating chloride ion influx, sodium oxybate induces sleep and muscle tone modulation through alternative pathways, ultimately contributing to its unique therapeutic benefits in narcolepsy treatment. Ongoing research aims to further delineate these pathways and to optimize therapeutic effects while minimizing adverse effects and misuse potential.

Pharmacological Actions

Acts as a central nervous system depressant by enhancing inhibitory neurotransmission.
Binds to GABAB receptors causing neuronal hyperpolarization and decreased neurotransmitter release.
Modulates GHB (gamma-hydroxybutyrate) receptors influencing dopaminergic and glutamatergic signaling.
Enhances slow-wave (deep) sleep, improving sleep architecture and restorative sleep.
Reduces excessive daytime sleepiness and frequency of cataplexy in narcolepsy patients.
Exerts muscle tone regulation through CNS depressant effects.
Has a rapid onset of sleep induction via central neuronal mechanisms.
Demonstrates dose-dependent CNS depressive effects with a defined therapeutic window.
Minimal protein binding facilitates brain penetration.
Undergoes extensive metabolism, limiting systemic toxicity.
Can induce physical dependence if used outside prescribed indications or doses.
Unique among sedative-hypnotics due to action on GHB-specific receptors.
Does not significantly involve cytochrome P450 enzymes, limiting drug interactions.
Possesses potential for misuse owing to euphoric and sedative effects at supra-therapeutic doses.

Therapeutic Or Clinical Uses

Treatment of cataplexy (sudden loss of muscle tone) in patients with narcolepsy aged 7 years and older.
Management of excessive daytime sleepiness (EDS) associated with narcolepsy in adults and pediatric patients.
Improvement of nighttime sleep quality by increasing slow-wave sleep duration.
Reduction in frequency and severity of narcolepsy symptoms leading to enhanced daily function.
Adjunct therapy for patients inadequately managed by traditional stimulants and antidepressants.
Off-label use is limited due to high abuse potential but theoretically considered for other hypersomnolence disorders under strict supervision.
Used as a therapeutic agent restricting sodium load in formulations like Xywav (low-sodium alternative).
Potential utility in research settings for sleep-related disorders due to unique mechanism of action.
Beneficial in narcolepsy patients with coexisting sleep disturbances refractory to other treatments.
Provides alternative to stimulant medications, especially for patients intolerant to such therapies.
Treatment initiation involves careful titration to balance efficacy and safety.
Monitored use under REMS program to mitigate risks of abuse and misuse.
Improves quality of life by addressing both sleep disruption and cataplexy.

Side Or Adverse Effects

Nausea – commonly reported especially at treatment initiation or dose escalation.
Somnolence and excessive sleepiness leading to daytime sedation or grogginess.
Dizziness and vertigo, which may impair balance especially during dosing or upon awakening.
Vomiting and gastrointestinal discomfort.
Nocturnal enuresis (bedwetting), particularly in pediatric populations.
Tremor or fine muscle shaking.
Headache, frequently reported in children.
Sleepwalking episodes which may lead to injury.
Confusion, altered mental status, and cognitive disturbances.
Hallucinations and unusual or disturbing thoughts, including paranoia or psychosis.
Depression and emergence of suicidal ideation or tendencies.
Respiratory depression possibly leading to hypoventilation or apnea events, especially in patients with preexisting pulmonary disease.
Low blood pressure (hypotension) causing dizziness or syncope.
Potential for physical dependence and withdrawal symptoms upon abrupt discontinuation.
Increased risk of falls and related injuries due to rapid onset of sleep or CNS depression.

Precautions

Administer only to patients enrolled in the Xywav and Xyrem REMS Program due to high risk of abuse and CNS depression.
Avoid concurrent use with other CNS depressants including opioids, benzodiazepines, alcohol, sedating antidepressants, antipsychotics, muscle relaxants, and anesthetics.
Use caution in patients with a history of substance abuse or dependence.
Monitor patients closely for signs of respiratory depression, especially those with asthma, COPD, sleep apnea, or other pulmonary disorders.
Carefully observe patients for emergent psychiatric symptoms such as depression, psychosis, or suicidal ideation.
Avoid activities requiring full alertness, such as driving or operating machinery, for at least 6 hours after dosing until individual response is known.
Exercise caution in patients with cardiovascular disease, hypertension, or on sodium-restricted diets due to the high sodium content of Xyrem.
Dose adjustment recommended in patients with liver impairment due to altered metabolism.
Pregnancy: Weigh benefits against risks; crosses placenta and CNS depression may affect fetus.
Breastfeeding: Sodium oxybate passes into breast milk; assess risk-benefit prior to use.
Children should remain in bed after dosing to reduce risk of falls from rapid sleep onset.
Ensure accurate adherence to dosing schedule; avoid overdose or double dosing.
Store securely to prevent accidental ingestion and ensure safety due to abuse potential.
Consider renal function when dosing; monitor for accumulation in severe impairment.
Educate patients and caregivers on the importance of compliance with the REMS program and safe medication handling.

Warnings

Boxed Warning: Risk of severe CNS depression including respiratory depression, coma, and death especially when combined with other CNS depressants.
High potential for abuse, misuse, and addiction; classified as Schedule III controlled substance under legitimate use and Schedule I when abused.
Fatal overdose risk particularly when combined with alcohol or other sedatives.
May cause serious respiratory depression manifesting as slowed or halted breathing.
Precaution against simultaneous use with alcohol or sedative hypnotics due to additive CNS depression.
Risk of severe hypotension and syncope with possible injury from falls.
Potential for sleepwalking and associated injuries; monitoring recommended.
May exacerbate preexisting psychiatric conditions or provoke new-onset mental health disturbances.
Avoid prescribing to patients with succinic semialdehyde dehydrogenase deficiency, a rare metabolic disorder.
Patients must be registered in REMS program with access restricted to certified pharmacies only.
Abrupt discontinuation may result in withdrawal symptoms; gradual tapering advised.
Secured storage and disposal are critical to prevent misuse or accidental ingestion by children or others.
Patients should be advised not to drive or perform hazardous tasks until they understand how Xyrem affects them.
Potential for legal consequences if sold or distributed outside authorized frameworks.
Strict adherence to dosing intervals is essential to minimize serious adverse outcomes.

Contraindication

Concurrent use with other sleep medicines or sedatives including benzodiazepines, opioids, and alcohol.
Known hypersensitivity to sodium oxybate or any component of the formulation.
Patients with succinic semialdehyde dehydrogenase deficiency due to incompatible metabolism.
Patients with untreated sleep apnea or severe respiratory compromise unless risks are carefully managed.
History of hypersomnia or hypersensitivity reactions to other central nervous system depressants.
Patients who are unable to comply with REMS program requirements.
Severe uncontrolled cardiovascular or renal disease without medical clearance.
Patients with recent or active substance abuse disorders unless adequately supervised.
Use during pregnancy unless the benefit outweighs potential fetal risk.
Breastfeeding unless risks are assessed and decided by healthcare provider.
Patients unable to remain in bed after dosing due to risk of injuries from rapid sleep onset.
Use in combination with other medications that prolong CNS depression is contraindicated.
Patients with severe hepatic impairment without dosage adjustment and medical supervision.
Any condition that precludes safe administration as determined by a healthcare provider.

Drug Interactions

Additive CNS depressant effect with opioids increasing risk of respiratory depression, coma, and death.
Concomitant use with benzodiazepines enhances sedation and respiratory depression.
Sedating antidepressants (such as tricyclics or trazodone) may potentiate hypotension and sedation.
Antipsychotic drugs may exacerbate CNS depressive effects and alter mental status.
Muscle relaxants combined with Xyrem can increase the risk of profound CNS depression.
General anesthetics used perioperatively may compound respiratory and cardiac depressive risks.
Alcohol markedly potentiates CNS depression, increasing risk of fatal overdose.
Sedating antiepileptic medications may increase sedation and impair cognitive function when combined.
Drugs affecting GABAergic transmission could alter or potentiate the effects of sodium oxybate.
No significant cytochrome P450 enzyme interactions identified, minimizing metabolic interactions.
Concurrent use with other sodium-containing medications may worsen sodium burden affecting cardiovascular health.
Doses of CNS stimulants for narcolepsy may require adjustment concurrent with Xyrem therapy.
Concomitant therapy with agents affecting respiratory drive should be closely monitored.
Potential alteration in blood pressure control when combined with antihypertensives.
Careful assessment required when combined with medications influencing mental health due to risk of additive psychiatric effects.

Preparations Of The Drug

Xyrem oral solution containing 0.5 g/mL sodium oxybate in a 180 mL bottle with child-resistant cap.
Pharmacy-provided measuring cups and dosing containers with child-resistant caps for dilution and administration.
Single-concentration formulation designed for dilution prior to dosing, ensuring dosing accuracy and safety.
Original bottles intended for storage prior to dilution; mixed solution stored in pharmacy-provided containers.
Storage recommendations include room temperature between 68°F and 77°F (20°C to 25°C).
Mixed solution should be consumed within 24 hours to maintain potency and safety.
Includes detailed Instruction for Use documentation describing patient preparation and dosing procedures.
Available only through certified pharmacies participating in the Xywav and Xyrem REMS Program.
Packaging designed with tamper-evident and child-resistant features to prevent accidental ingestion and diversion.
Alongside active ingredient sodium oxybate, inactive ingredients include purified water and malic acid for solution stability.
Special handling instructions for disposal of unused or expired Xyrem solution including emptying down sink and destroying labels.
Distribution restricted to ensure controlled access due to abuse potential and risk of severe side effects.
Contains significant sodium load per dose, necessitating patient counseling and monitoring in populations sensitive to salt intake.